Immunai Analysis: $275M Raised
What is Immunai?
Immunai specializes in mapping the immune system at an unprecedented scale and resolution. Their unique approach integrates multi-omic data with advanced machine learning to enhance drug discovery and development. This enables biopharmaceutical companies to make informed decisions, reducing risks and accelerating the development of immune-related therapeutics.
HQ Country
New York, United States
Employees
51-200
Founded
2018
Industry
HealthTech, Biotech, AI/ML
Product Features & Capabilities
- Target Discovery for identifying novel disease-linked targets
- Preclinical Evaluation to prioritize promising drug candidates
- Clinical Trial Optimization for understanding drug mechanisms and patient groups
- Multi-Omic Immune Sequencing for comprehensive immune profiling
- AMICA database integration for enhanced analytical insights.
How much Immunai raised
Seed - N/A
May 14, 2020Lead Investor: TLV Partners, Viola Group
Series A - $60 million
February 11, 2021Lead Investor: Catalio Capital Management, Charles and Lynn Schusterman Family Philanthropies, Dexcel Pharma, Duquesne Family Office
Series B - $215 million
October 27, 2021Lead Investor: Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, among others
Financial Overview
$275MTotal Raised
Seed
May 14, 2020
Investors: TLV Partners, Viola Group
Series A$60 million
February 11, 2021
Investors: Catalio Capital Management, Charles and Lynn Schusterman Family Philanthropies, Dexcel Pharma, Duquesne Family Office
Series B$215 million
October 27, 2021
Investors: Koch Disruptive Technologies, Talos VC, 8VC, Alexandria Venture Investments, Piedmont, ICON, among others
